Immunologically relevant aspects of the new COVID-19 vaccines —an ÖGAI (Austrian Society for Allergology and Immunology) and AeDA (German Society for Applied Allergology) position paper

ConclusionDespite the need for a  patient-specific risk–benefit assessment, the consensus among experts is that patients with immunological diseases in particular benefit from the induced immune protection after COVID-19 vaccination and do not have an increased risk of side effects.
Source: Allergo Journal International - Category: Allergy & Immunology Source Type: research